Cancers of the head and neck are common, and this review aimed to systematically analyze the safety and efficacy of anti-PD1/PD-L1 inhibitors (API) therapies in head and neck squamous cell carcinoma (HNSCC). Here, PDCD1 is linked to head and neck cancer.